The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. presented new research at the ARVO2026 conference, introducing automation to reduce variability in quantitative autofluorescence measurements for patients with geographic atrophy and Stargardt disease.
The company underscored its commitment to supporting innovation aimed at advancing research for blindness-related conditions, reflecting ongoing efforts to improve diagnostic methodologies in ophthalmology. The presentation further signals the growing integration of automation in clinical research for retinal diseases.
Ocugen recently reported a 31 percent reduction in geographic atrophy lesion growth with its OCU410 medium dose in a phase 2 trial, along with improved EZ preservation in clinical results. The company has also detailed plans to file three biologics license applications by 2028 to expand access to gene therapies for blindness in a mass-market strategy. These developments follow ongoing research efforts in retinal disease diagnostics and treatment.